{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG000","lowerLimit":"12.7","upperLimit":"NA","value":"21.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"Estimated using the product-limit method of Kaplan and Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cycle 1, stem cell mobilization with granulocyte-colony stimulating factor (G-CSF) at 10 μg/kg/d subcutaneously prior to leukapheresis. G-CSF administration daily during collection until the total collected product excelled 4 × 106 CD34+ cells/kg. 24-hour IV infusion of paclitaxel at 350 mg/m2 or 425 mg/m2 on day -7. Subsequent to this, patients receive etoposide (20 mg/kg IV over 2 hours) and carboplatin (AUC of 7 mg-min/mL IV over 30 minutes) daily on days -6, -5 and -4. IV infusion of 12.5% of the derived CD34+ stem cell product on day -2, followed by administration of 37.5% of the product on day 0. Cycle 2, comprised of paclitaxel, ifosfamide and carboplatin. Ifosfamide administered IV daily at 3 g/m2 over 30 minutes on days -6, -5 and -4. Mesna administered 24 hours subsequently as a 1 g/m2 bolus dose followed by 10g/m2 via continuous IV infusion over 72 hours. The derived CD34+ stem cell product administered in a manner identical to that during Cycle 1 on days -2 and 0.","id":"OG000","title":"HD Chemo and Auto Stem Cells"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Until death from any cause, up to 5 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}